BRIEF-Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy

Reuters09-19

Sept 19 (Reuters) - Achilles Therapeutics PLC :

* ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE

* ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY

* ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO PROVIDE STRATEGIC FINANCIAL ADVICE

* ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION

* ACHILLES THERAPEUTICS PLC SAYS AS OF JUNE 30, 2024, COMPANY HAD $95.1 MILLION IN CASH AND CASH EQUIVALENTS

* ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES MAY INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS COMBINATION, ASSET SALE, LICENSING

* ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH THIRD PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL NEOANTIGENS

* ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC REVIEW

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468189578?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468189578","market":"us","top_or_hot":-1,"title":"BRIEF-Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy","media":"Reuters","content":"<html><body><p>Sept 19 (Reuters) - Achilles <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/PLC\">PLC</a>   :</p><p>   * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE</p><p>   * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY</p><p>   * ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO PROVIDE STRATEGIC FINANCIAL ADVICE</p><p>   * ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION</p><p>   * ACHILLES THERAPEUTICS PLC SAYS  AS OF JUNE 30, 2024, COMPANY HAD $95.1 MILLION IN CASH AND CASH EQUIVALENTS</p><p>   * ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES MAY INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS COMBINATION, ASSET SALE, LICENSING</p><p>   * ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH THIRD PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL NEOANTIGENS</p><p>   * ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC REVIEW</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 19 (Reuters) - Achilles Therapeutics PLC   :   * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE   * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2468189578","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468189578","pubTimestamp":1726746018,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 19  - Achilles Therapeutics PLC   :   * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE   * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY   * ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO PROVIDE STRATEGIC FINANCIAL ADVICE   * ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION   * ACHILLES THERAPEUTICS PLC SAYS  AS OF JUNE 30, 2024, COMPANY HAD $95.1 MILLION IN CASH AND CASH EQUIVALENTS   * ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES MAY INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS COMBINATION, ASSET SALE, LICENSING   * ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH THIRD PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL NEOANTIGENS   * ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC REVIEWSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ACHL":"Achilles Therapeutics plc","BK4505":"高瓴资本持仓","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"简介-Achilles Therapeutics将停止开发基于TIL的cNET疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHL":1,"LENZ":1},"content_text":"Sept 19 (Reuters) - Achilles Therapeutics PLC   :   * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE   * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY   * ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO PROVIDE STRATEGIC FINANCIAL ADVICE   * ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION   * ACHILLES THERAPEUTICS PLC SAYS  AS OF JUNE 30, 2024, COMPANY HAD $95.1 MILLION IN CASH AND CASH EQUIVALENTS   * ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES MAY INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS COMBINATION, ASSET SALE, LICENSING   * ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH THIRD PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL NEOANTIGENS   * ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC REVIEWSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468189578"}